[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594330":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":31,"collaborators":7,"id":33,"slug":7,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":7,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"Regina Elena Cancer Institute","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Fabio Calabrò, Doctor","CONTACT","+39 0652666271","fabio.calabro@ifo.it",[15],{"facility":16,"status":17,"city":18,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"\"Regina Elena\" National Cancer Institute","RECRUITING","Rome","00144","Italy","IT",{"type":23,"coordinates":24},"Point",[25,26],12.51133,41.89193,{"lat":26,"lon":25},[29],{"name":30,"role":11,"phone":12,"phoneExt":7,"email":13},"Fabio Calabrò",{"type":32,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100594330",false,"NCT07018037","Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma","Pilot Study to Describe the Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma","TTV ccRCC","Inclusion Criteria:\n\n* Patients over 18 years of age;\n* Histological diagnosis of clear cell renal cell carcinoma;\n* Evidence of advanced or metastatic disease;\n* Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI);\n* Patients able to comply with the study procedures.\n* Patients who give written informed consent personally or through a witness (study participation and data processing), before any study-specific procedure is started.\n\nExclusion Criteria:\n\n* Previous neoplasms;\n* Previous antineoplastic treatments;\n* Previous steroid treatments;\n* Active viral infections (e.g., HCV, HIV, etc.);\n* Lack of autonomy in adhering to study procedures.","ALL","18 Years",{"count":43,"type":44},20,"ESTIMATED","OBSERVATIONAL","The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.",[48],"Renal Cell Carcinoma",[50],"Torquetenovirus (TVV)","2026-06-04",{"date":53,"type":54},"2026-06-05","ACTUAL",{"date":56,"type":54},"2025-01-29",{"date":58,"type":44},"2027-01-29",{"name":5,"class":6},1]